More recently, SGLT2 inhibitors – used in the management of type 2 diabetes and chronic kidney disease – have been shown to lower serum urate levels and may reduce gout incidence while offering cardiovascular and renal protection [62]. This evidence concerns the gene SLC5A2 and gout.